An observational study in Gastroesophageal Reflux Disease, sponsored by AstraZeneca. Completed at 19 sites in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-06.
Sponsored by AstraZeneca · Observational
The present study has been designed to provide current data on GERD prevalence in several regional areas of Greece outside the two major urban centres (Athens and Thessaloniki), to measure the treatment response in GERD patients, and to assess the correlations between the two methods of diagnosing GERD, i.e. reporting of symptoms by the patient to the physician and completion of the GerdQ questionnaire by the patient. Additionally, this study aims to provide data on the prevalence of extraesophageal symptoms in GERD patients in Greece. The XQS questionnaire will be applied for the identification of these patients and the assessment of the extraesophageal disease burden (frequency and intensity/severity). Finally, an association between the GerdQ and XQS scores will be attempted.
1,067 studies on the registry are indexed under Gastroesophageal Reflux; 188 are open to participants now.
This study's enrollment of 600 is above the median of 180 across 298 observational studies indexed under Gastroesophageal Reflux.
Browse Gastroesophageal Reflux studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with upper GI symptoms
Exclusion Criteria:
patients with upper GI symptoms, visiting the outpatient departments of peripheral hospitals in Greece
GerdQ score
Time frame: End of recruitment (estimated timeframe :2.5 months)
Demographic data (age, gender, race, weight, height)
Time frame: End of recruitment (estimated timeframe :2.5 months)
Marital status
Time frame: End of recruitment (estimated timeframe :2.5 months)
Smoking habits, alcohol consumption
Time frame: End of recruitment (estimated timeframe :2.5 months)
Patient's eating habits and implementation of dietary recommendations
Time frame: End of recruitment (estimated timeframe :2.5 months)
Place of residence (urban, suburban, rural)
Time frame: End of recruitment (estimated timeframe :2.5 months)
Education level
Time frame: End of recruitment (estimated timeframe :2.5 months)
Occupation
Time frame: End of recruitment (estimated timeframe :2.5 months)
General medical history
Time frame: End of recruitment (estimated timeframe :2.5 months)
History of upper gastrointestinal diseases
Time frame: End of recruitment (estimated timeframe :2.5 months)
Way of antisecretory treatment administration for GI symptoms the last month prior to study visit (if applicable)
Time frame: End of recruitment (estimated timeframe :2.5 months)
Compliance to antisecretory treatment (if applicable)
Time frame: End of recruitment (estimated timeframe :2.5 months)
Upper GI symptomatology XQS score
Time frame: End of recruitment (estimated timeframe :2.5 months)
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca